Coronary artery disease is a leading cause of death worldwide and the largest killer of men and women in the United States. The pathophysiology of myocardial infarction is multifactorial, and numerous physiologic systems converge to dictate the formation of the two fundamental lesions, thrombosis and atherosclerosis. In this review we address genetic aspects of arterial thrombosis and the key thrombotic factors that have been associated with the increased risk for its development. Specifically, we consider components of coagulation, fibrinolysis, and Platelet adhesive receptors, and we review the genetic epidemiology and in vitro laboratory data regarding their risk for the acute coronary syndromes. In combination with traditional risk factor assessment, in the near future these inherited markers can be used to manage patients with vascular disease through a better utilization of invasive or expensive diagnostic testing, as well as pharmacologic intervention.
American Heart Association. 2000 Heart and stroke statistical update. Dallas: American Heart Association, 1999.
2.
SingCF, HavilandMB, TempletonAR, ZerbaKE, ReillySL. Biological complexity and strategies for finding DNA variations responsible for inter-individual variation in risk of a common chronic disease, coronary artery disease. Ann Med24:539–547, 1992.
3.
ThordarsonO, FridrikssonS.Aggregation of deaths from ischaemic heart disease among first- and second-degree relatives of 108 males and 42 females with myocardial infarction. Acta Med Scand205:493–500, 1979.
4.
RissanenAM, NikkilaEA. Coronary artery disease and its risk factors in families of young men with angina pectoris and in controls. Br Heart J39:875–883, 1977.
SlackJ, EvansKA. The increased risk of death from ischaemic heart disease in first-degree relatives of 121 men and 96 women with ischaemic heart disease. J Med Genet3:329–357, 1966.
7.
JordeLB, WilliamsRR. Relation between family history of coronary artery disease and coronary risk variables. Am J Cardiol62:708–713, 1988.
8.
RissanenAM. Familial occurrence of coronary heart disease: Effect of age at diagnosis. Am J Cardiol44:60–66, 1979.
9.
BergK.The genetics of the hyperlipidemias and coronary artery disease. Prog Clin Biol Res103(Pt B):111–125, 1982.
10.
SorensenTI, NielsenGG, AndersenPK, TeasdaleTW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med318:727–732, 1988.
11.
HarvaldB, HaugeM.Coronary occlusion in twins. Acta Genet Med Gemellol (Roma)19:248–250, 1970.
12.
MarenbergME, RischN, BerkmanLF, FloderusB, de FaireU.Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med330:1041–1046, 1994.
13.
PastinenT, PerolaM, NiiniP, TerwilligerJ, SalomaaV, VartiainenE, PeltonenL, SyvanenA.Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Mol Genet7:1453–1462, 1998.
14.
BreslowJL, DammermanM.Genetic determinants of myocardial infarction. Adv Exp Med Biol369:65–78, 1995.
15.
CanessaM.The polymorphism of red cell Na and K transport in essential hypertension: Findings, controversies, and perspectives. Prog Clin Biol Res159:293–315, 1984.
16.
SoubrierF, CambienF.The angiotensin I-converting enzyme gene polymorphism: Implication in hypertension and myocardial infarction. Curr Opin Nephrol Hypertens3:25–29, 1994.
SchaferAI. Hypercoagulable states: Molecular genetics to clinical practice. Lancet344:1739–1742, 1994.
19.
FredricksonBJ, DongJF, McIntireLV, LópezJA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood92:3684–3693, 1998.
20.
SavageB, Almus-JacobsF, RuggeriZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell94:657–666, 1998.
FusterV, BadimonL, CohenM, AmbroseJA, BadimonJJ, ChesebroJ.Insights into the pathogenesis of acute ischemic syndromes. Circulation77:1213–1220, 1988.
23.
DangCV, BellWR, ShumanM.The normal and morbid biology of fibrinogen. Am J Med87:567–576, 1989.
24.
MeadeTW, MellowsS, BrozovicM, MillerGJ, ChakrabartiRR, NorthWR, HainesAP, StirlingY, ImesonJD, ThompsonSG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet2:533–537, 1986.
25.
WilhelmsenL, SvardsuddK, Korsan-BengtsenK, LarssonB, WelinL, TibblinG.Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med311:501–550, 1984.
26.
ErikssonM, EgbergN, WamalaS, Orth-GomerK, MittlemanMA, Schenck-GustafssonK.Relationship between plasma fibrinogen and coronary heart disease in women. Arterioscler Thromb Vasc Biol19:67–72, 1999.
27.
KannelWB, WolfPA, CastelliWP, D'AgostinoRB. Fibrinogen and risk of cardiovascular disease: The Framingham Study. J Am Med Assoc258:1183–1186, 1987.
28.
ErnstE, ReschKL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med118:956–963, 1993.
29.
MarescaG, Di BlasioA, MarchioliR, Di MinnoG.Measuring plasma fibrinogen to predict stroke and myocardial infarction: An update. Arterioscler Thromb Vasc Biol19:1368–1377, 1999.
30.
HumphriesSE, CookM, DubowitzM, StirlingY, MeadeTW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet1:1452–1455, 1987.
31.
ThomasA, LamlumH, HumphriesS, GreenF.Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G/A–455 (HaeIII), C/T–148 (HindIII/AluI), T/G+1689 (AvaII), and BclI (β-fibrinogen) and TaqI (α-fibrinogen), and their detection by PCR. Hum Mutat3:79–81, 1994.
32.
MargaglioneM, CappucciG, ColaizzoD, PirroL, VecchioneG, GrandoneE, Di MinnoG.Fibrinogen plasma levels in an apparently healthy general population: Relation to environmental and genetic determinants. Thromb Haemost80:805–810, 1998.
33.
BehagueI, PoirierO, NicaudV, EvansA, ArveilerD, LucG, CambouJP, ScarabinPY, BaraL, GreenF, CambienF.β Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: The ECTIM Study. Circulation93:440–449, 1996.
34.
CarterAM, MansfieldMW, StricklandMH, GrantPJ. Beta-fibrinogen gene-455 G/A polymorphism and fibrinogen levels: Risk factors for coronary artery disease in subjects with NIDDM. Diabetes Care19:1265–1268, 1996.
35.
YuQ, SafaviF, RobertsR, MarianAJ. A variant of beta fibrinogen is a genetic risk factor for coronary artery disease and myocardial infarction. J Invest Med44:154–159, 1996.
36.
ZitoF, Di CastelnuovoA, AmoreC, D'OrazioA, DonatiMB, IacovielloL.Bcl I polymorphism in the fibrinogen β-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels: A case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol17:3489–3494, 1997.
37.
ScarabinPY, BaraL, RicardS, PoirierO, CambouJP, ArveilerD, LucG, EvansAE, SamamaMM, CambienF.Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction: The ECTIM Study. Arterioscler Thromb13:886–891, 1993.
38.
MansfieldMW, SticklandMH, GrantPJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost74:842–847, 1995.
39.
GrenettHE, BenzaRL, LiXN, AikensML, GrammerJR, BrownSL, BooyseFM. Expression of plasminogen activator inhibitor type I in genotyped human endothelial cell cultures: Genotype-specific regulation by insulin. Thromb Haemost82:1504–1509, 1999.
40.
DawsonSJ, WimanB, HamstenA, GreenF, HumphriesS, HenneyAM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem268:10739–10745, 1993.
41.
ErikssonP, KallinB, 't HooftFM, BavenholmP, HamstenA.Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA92:1851–1855, 1995.
42.
HamstenA, WimanB, de FaireU, BlombackM.Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med313:1557–1563, 1985.
43.
MeadeTW, RuddockV, StirlingY, ChakrabartiR, MillerGJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet342:1076–1079, 1993.
44.
ThogersenAM, JanssonJH, BomanK, NilssonTK, WeinehallL, HuhtasaariF, HallmansG.High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation98:2241–2247, 1998.
45.
HamstenA, de FaireU, WalldiusG, DahlenG, SzamosiA, LandouC, BlombackM, WimanB.Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet2:3–9, 1987.
46.
ScarabinPY, AillaudMF, AmouyelP, EvansA, LucG, FerneresJ, ArveilerD, Juhan-VagueI.Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction: The PRIME Study. Thromb Haemost80:749–756, 1998.
47.
GranchaS, EstellesA, TormoG, FalcoC, GilabertJ, EspanaF, CanoA, SeguiR, AznarJ.Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost81:516–521, 1999.
48.
AndersonJL, MuhlesteinJB, HabashiJ, CarlquistJF, BairTL, ElmerSP, DavisBP. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol34:1778–1783, 1999.
49.
RidkerPM, HennekensCH, LindpaintnerK, StampferMJ, MiletichJP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of U.S. men. Circulation95:59–62, 1997.
50.
YeS, GreenFR, ScarabinPY, NicaudV, BaraL, DawsonSJ, HumphriesSE, EvansA, LucG, CambouJP. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost74:837–841, 1995.
51.
IacovielloL, BurzottaF, Di CastelnuovoA, ZitoF, MarchioliR, DonatiMB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis. Thromb Haemost80:1029–1030, 1998.
52.
GreenbergCS, BirckbichlerPJ, RiceRH. Transglutaminases: Multifunctional cross-linking enzymes that stabilize tissues. FASEB J5:3071–3077, 1991.
53.
FrancisCW, ConnaghanDG, ScottWL, MarderVJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation75:1170–1177, 1987.
54.
KohlerHP, GrantPJ. Clustering of haemostatic risk factors with FXIIIVal34Leu in patients with myocardial infarction. Thromb Haemost80:862, 1998.
55.
WartiovaaraU, PerolaM, MikkolaH, TottermanK, SavolainenV, PenttilaA, GrantPJ, TikkanenMJ, VartiainenE, KarhunenPJ, PeltonenL, PalotieA.Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis142:295–300, 1999.
56.
NakagakiT, FosterDC, BerknerKL, KisielW.Initiation of the extrinsic pathway of blood coagulation: Evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry30:10819–10824, 1991.
57.
GreenF, KelleherC, WilkesH, TempleA, MeadeT, HumphriesS.A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb11:540–546, 1991.
58.
HunaultM, ArbiniAA, LopaciukS, CarewJA, BauerKA. The Arg353Gln polymorphism reduces the level of coagulation factor VII: In vivo and in vitro studies. Arterioscler Thromb Vasc Biol17:2825–2829, 1997.
59.
HongY, PedersenNL, EgbergN, de FaireU.Genetic effects for plasma factor VII levels independent of and in common with triglycerides. Thromb Haemost81:382–386, 1999.
60.
IacovielloL, Di CastelnuovoA, de KnijffP, D'OrazioA, AmoreC, ArborettiR, KluftC, BenedettaDM. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med338:79–85, 1998.
61.
DoggenCJ, CatsVM, BertinaRM, RosendaalFR. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20010A. Circulation97:1037–1041, 1998.
62.
CorralJ, Gonzalez-ConejeroR, LozanoML, RiveraJ, VicenteV.Genetic polymorphisms of factor VII are not associated with arterial thrombosis. Blood Coagul Fibrinolysis9:267–272, 1998.
63.
HeywoodDM, Ossei-GemingN, GrantPJ. Association of factor VII:C levels with environmental and genetic factors in patients with ischaemic heart disease and coronary atheroma characterised by angiography. Thromb Haemost76:161–165, 1996.
64.
LaneA, GreenF, ScarabinPY, NicaudV, BaraL, HumphriesS, EvansA, LucG, CambouJP, ArveilerD, CambienF.Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis119:119–127, 1996.
65.
JunkerR, HeinrichJ, SchulteH, van de LooJ, AssmannG.Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol17:1539–1544, 1997.
66.
RevakSD, CochraneCG. The relationship of structure and function in human Hageman factor: The association of enzymatic and binding activities with separate regions of the molecule. J Clin Invest57:852–860, 1976.
67.
RevakSD, CochraneCG, BoumaBN, GriffinJH. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med147:719–729, 1978.
68.
KohlerHP, CarterAM, SticklandMH, GrantPJ. Levels of activated FXII in survivors of myocardial infarction: Association with circulating risk factors and extent of coronary artery disease. Thromb Haemost79:14–18, 1998.
69.
KanajiT, OkamuraT, OsakiK, KuroiwaM, ShimodaK, HamasakiN, NihoY.A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood91:2010–2014, 1998.
70.
PoortSR, RosendaalER, ReitsmaPH, BertinaRM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood88:3698–3703, 1996.
71.
HillarpA, ZollerB, SvenssonPJ, DahlbackB.The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost78:990–992, 1997.
72.
KapurRK, MillsLA, SpitzerSG, HultinMB. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol17:2875–2879, 1997.
73.
CroftSA, DalyME, SteedsRP, ChannerKS, SamaniNJ, HamptonKK. The prothrombin 20210A allele and its association with myocardial infarction. Thromb Haemost81:861–864, 1999.
74.
ArrudaVR, Annichino-BizzacchiJM, GoncalvesMS, CostaFF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost78:1430–1433, 1997.
75.
CorralJ, Gonzalez-ConejeroR, LozanoML, RiveraJ, HerasI, VicenteV.The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol99:304–307, 1997.
76.
FerraresiP, MarchettiG, LegnaniC, CavallariE, CastoldiE, MascoliF, ArdissinoD, PalaretiG, BernardiF.The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol17:2418–2422, 1997.
77.
RidkerPM, HennekensCH, MiletichJP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of U.S. men. Circulation99:999–1004, 1999.
78.
RosendaalFR, SiscovickDS, SchwartzSM, PsatyBM, RaghunathanTE, VosHL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood90:1747–1750, 1997.
79.
DahlbackB.Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost78:483–488, 1997.
80.
RidkerPM, HennekensCH, LindpaintnerK, StampferMJ, EisenbergPR, MiletichJP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med332:912–917, 1995.
81.
ArdissinoD, PeyvandiF, MerliniPA, ColombiE, MannucciPM. Factor V (Arg 506→Gln) mutation in young survivors of myocardial infarction. Thromb Haemost75:701–702, 1996.
82.
CushmanM, RosendaalFR, PsatyBM, CookEF, ValliereJ, KullerLH, TracyRP. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: Results from the Cardiovascular Health Study. Thromb Haemost79:912–915, 1998.
83.
RosendaalFR, SiscovickDS, SchwartzSM, BeverlyRK, PsatyBM, LongstrethWTJ, RaghunathanTE, KoepsellTD, ReitsmaPH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood89:2817–2821, 1997.
84.
NygardO, NordrehaugJE, RefsumH, UelandPM, FarstadM, VollsetSE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med337:230–236, 1997.
85.
StampferMJ, MalinowMR, WillettWC, NewcomerLM, UpsonB, UllmannD, TishlerPV, HennekensCH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. J Am Med Assoc268:877–881, 1992.
86.
FrosstP, BlomHJ, MilosR, GoyetteP, SheppardCA, MatthewsRG, BoersGJ, den HeijerM, KluijtmansLA, van den HeuvelLP. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet10:111–113, 1995.
87.
AndersonJL, KingGJ, ThomsonMJ, ToddM, BairTL, MuhlesteinJB, CarlquistJF. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol30:1206–1211, 1997.
88.
GirelliD, FrisoS, TrabettiE, OlivieriO, RussoC, PessottoR, FacciniG, PignattiPF, MazzuccoA, CorrocherR.Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: Evidence for an important genetic-environmental interaction. Blood91:4158–4163, 1998.
89.
MaJ, StampferMJ, HennekensCH, FrosstP, SelhubJ, HorsfordJ, MalinowMR, WillettWC, RozenR.Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in U.S. physicians. Circulation94:2410–2416, 1996.
90.
SchmitzC, LindpaintnerK, VerhoefP, GazianoJM, BuringJ.Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: A case-control study. Circulation94:1812–1814, 1996.
91.
BrattstromL, WilckenDE, OhrvikJ, BrudinL.Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation98:2520–2526, 1998.
DoggenCJ, KunzG, RosendaalFR, LaneDA, VosHL, StubbsPJ, MangerC, V, IrelandH.A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost80:743–748, 1998.
NorlundL, HolmJ, ZollerB, OhlinAK. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost77:248–251, 1997.
96.
KeightleyAM, LamYM, BradyJN, CameronCL, LillicrapD.Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF: Ag levels: Identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood93:4277–4283, 1999.
97.
HeywoodDMH, Ossei-GerningN, GrantPJ. Two novel polymorphisms of the von Willebrand factor gene promoter and association with ischemic heart disease. Thromb Haemost78:375A, 1997.
98.
The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: The EPIC Investigation. N Engl J Med 330:956–961, 1994.
99.
The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689–1696, 1997.
100.
The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein Ilb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 338:1488–1497, 1998.
101.
The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: The RESTORE Investigators. Circulation 96:1445–1453, 1997.
102.
NewmanPJ, DerbesRS, AsterRH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest83:1778–1781, 1989.
103.
van LoghemJJ, DorfmeyerH, van der HartM, SchreuderF.Serological and genetical studies on a platelet antigen (Zw). Vox Sang4:161–169, 1959.
104.
WeissEJ, BrayPF, TaybackM, SchulmanSP, KicklerTS, BeckerLC, WeissJL, GerstenblithG, Goldschmidt-ClermontPJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med334:1090–1094, 1996.
105.
AndersonJL, KingGJ, BairTL, ElmerSP, MuhlesteinJB, HabashiJ, CarlquistJF. Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. J Am Coll Cardiol33:727–733, 1999.
ArdissinoD, MannucciPM, MerliniPA, DucaF, FetiveauR, TagliabueL, TubaroM, GalvaniM, OttaniF, FerrarioM, CorralJ, MargaglioneM.Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood94:46–51, 1999.
108.
CorralJ, Gonzalez-ConejeroR, RiveraJ, IniestaJA, LozanoML, VicenteV.HPA-1 genotype in arterial thrombosis: Role of HPA-1b polymorphism in platelet function. Blood Coagul Fibrinolysis8:284–290, 1997.
109.
Garcia-RibesM, Gonzalez-LamunoD, Hernandez-EstefaniaR, ColmanT, PocoviM, Delgado-RodriguezM, Garcia-FuentesM, RevueltaJM. Polymorphism of the platelet glycoprotein IIIa gene in patients with coronary stenosis. Thromb Haemost79:1126–1129, 1998.
110.
HerrmannSM, PoirierO, Marques-VidalP, EvansA, ArveilerD, LucG, EmmerichJ, CambienF.The Leu33/Pro polymorphism (PlA1/PlA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Thromb Haemost77:1179–1181, 1997.
111.
HooperWC, LallyC, AustinH, BensonJ, DilleyA, WengerNK, WhitsettC, RawlinsP, EvattBL. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans. Chest116:880–886, 1999.
112.
KekomakiS, HamalainenL, Kauppinen-MakelinR, PalomakiH, KasteM, KontulaK.Genetic polymorphism of platelet glycoprotein IIIa in patients with acute myocardial infarction and acute ischaemic stroke. J Cardiovasc Risk6:13–17, 1999.
113.
ScaglioneL, BergeroneS, GaschinoG, ImazioM, MaccagnaniA, GambinoR, CassaderM, Di LeoM, MacchiaG, BruscaA, PaganoG, Cavallo-PerinP.Lack of relationship between the PlA1/PlA2 polymorphism of platelet glycoprotein IIIa and premature myocardial infarction. Eur J Clin Invest28:385–388, 1998.
114.
MamotteCD, van BockxmeerFM, TaylorRR. Pla1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol82:13–16, 1998.
115.
RidkerPM, HennekensCH, SchmitzC, StampferMJ, LindpaintnerK.plA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet349:385–388, 1997.
116.
ZotzRB, WinkelmannBR, NauckM, GiersG, Maruhn-DebowskiB, MarzW, ScharfRE. Polymorphism of platelet membrane glycoprotein IIIa: Human platelet antigen 1b (HPA-1b/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost79:731–735, 1998.
117.
KastratiA, SchomigA, SeyfarthM, KochW, EleziS, BottigerC, MehilliJ, SchomigK, von BeckerathN.PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation99:1005–1010, 1999.
118.
LauleM, CascorbiI, StanglV, BieleckeC, WerneckeKD, MrozikiewiczPM, FelixSB, RootsI, BaumannG, StanglK.A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: A case-controlled study. Lancet353:708–712, 1999.
119.
WalterDH, SchachingerV, ElsnerM, DimmelerS, ZeiherAM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet350:1217–1219, 1997.
120.
ZotzRB, KleinM, DaubenHP, MoserC, GamsE, ScharfRE. Prospective analysis after coronary-artery bypass grafting: Platelet GP IIIa polymorphism (HPA-1b/PlA2) is a risk factor for bypass occlusion, myocardial infarction, and death [In Process Citation]. Thromb Haemost83:404–407, 2000.
121.
CarterAM, Ossei-GerningN, WilsonIJ, GrantPJ. Association of the platelet PlA polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bβ 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation96:1424–1431, 1997.
122.
Durante-MangoniE, DaviesGJ, AhmedN, RuggieroG, TuddenhamEG. Coronary thrombosis and the platelet glycoprotein IIIA gene PLA2 polymorphism. Thromb Haemost80:218–219, 1998.
123.
GardemannA, HummeJ, StrickerJ, NguyenQD, KatzN, PhilippM, TillmannsH, HehrleinFW, RauM, HaberboschW.Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost80:214–217, 1998.
124.
MikkelssonJ, PerolaM, LaippalaP, SavolainenV, PajarinenJ, LaluK, PenttilaA, KarhunenPJ. Glycoprotein IIIa Pl(A) polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol19:2573–2578, 1999.
125.
CarterAM, CattoAJ, BamfordJM, GrantPJ. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol18:1124–1131, 1998.
BennettJS, VilaireG, Catella-LawsonF, RutAR, FitzgeraldG.The PlA2 alloantigen does not alter the affinity of GPIIb-IIIa for fibrinogen or RGD-containing peptides. Blood90:154a. 1997.
131.
GoodallAH, CurzenN, PanesarM, HurdC, KnightCJ, OuwehandWH, FoxKM. Increased binding of fibrinogen to glycoprotein IIIa-proline 33-(HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J20:742–747, 1999.
132.
MeiklejohnDJ, UrbaniakSJ, GreavesM.Platelet glycoprotein IIIa polymorphism HPA 1b (PlA2): No association with platelet fibrinogen binding. Br J Haematol105:664–666, 1999.
133.
VijayanKV, Goldschmidt-ClermontPJ, RoosC, BrayPF. The PlA2 polymorphism of integrin β3 enhances outside-in signaling and adhesive functions. J Clin Invest105:793–802, 2000.
134.
KritzikM, SavageB, NugentDJ, SantosoS, RuggeriZM, KunickiTJ. Nucleotide polymorphisms in the α2 gene define multiple alleles that are associated with differences in platelet α2β1 density. Blood92:2382–2388, 1998.
135.
CarlssonLE, SantosoS, SpitzerC, KesslerC, GreinacherA.The α2 gene coding sequence T807/A873 of the platelet collagen receptor integrin α2β1 might be a genetic risk factor for the development of stroke in younger patients. Blood93:3583–3586, 1999.
136.
CorralJ, Gonzalez-ConejeroR, RiveraJ, OrtunoF, AparicioP, VicenteV.Role of the 807 C/T polymorphism of the α2 gene in platelet GP Ia collagen receptor expression and function: Effect in thromboembolic diseases. Thromb Haemost81:951–956, 1999.
137.
CroftSA, HamptonKK, SorrellJA, SteedsRP, ChannerKS, SamaniNJ, DalyME. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol106:771–776, 1999.
138.
MoshfeghK, WuilleminWA, RedondoM, LammleB, BeerJH. Liechti-Gallati S, Meyer BJ. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: A case-control study. Lancet353:351–354, 1999.
139.
SantosoS, KunickiTJ, KrollH, HaberboschW, GardemannA.Association of the platelet glycoprotein la C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood93:2449–2453, 1999.
140.
CorralJ, LozanoML, Gonzalez-ConjeroR, MartinezC, IniestaJA, RiveraJ, VicenteV.A common polymorphism flanking the ATG initiator codon of GPIb alpha does not affect expression and is not a major risk factor for arterial thrombosis. Thromb Haemost83:23–28, 2000.
141.
Gonzalez-ConejeroR, LozanoML, RiveraJ, CorralJ, IniestaJA, MoraledaJM, VicenteV.Polymorphisms of platelet membrane glycoprotein Iba associated with arterial thrombotic disease. Blood92:2771–2776, 1998.
SonodaA, MurataM, ItoD, TanahashiN, OhtaA, TadaY, TakeshitaE, YoshidaT, SaitoI, YamamotoM, IkedaY, FukuuchiY, WatanabeK.Association between platelet glycoprotein Iba genotype and ischemic cerebrovascular disease. Stroke31:493–497, 2000.
144.
KuijpersRWAM, FaberNM, CuypersHTM, OuwehandWH, von dem BorneAEGK. NH2-terminal globular domain of human platelet glycoprotein Iba has a methionine 145/threonine 145 amino acid polymorphism, which is associated with the HPA-2 (Ko) alloantigens. J Clin Invest89:381–384, 1992.
145.
Afshar-KharghanV, LiCQ, Khoshnevis-AslM, LópezJA. Kozak sequence polymorphism of the glycoprotein (GP) Iba gene is a major determinant of the plasma membrane levels of the platelet GP ib-IX-V complex. Blood94:186–191, 1999.
146.
BoyleJJ. Association of coronary plaque rupture and atherosclerotic inflammation. J Pathol181:93–99, 1997.
147.
YudkinJS, KumariM, HumphriesSE, Mohamed-AliV.Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?Atherosclerosis148:209–214, 2000.
148.
RidkerPM, CushmanM, StampferMJ, TracyRP, HennekensCH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med336:973–979, 1997.
149.
TataruMC, HeinrichJ, JunkerR, SchulteH, von EckardsteinA, AssmannG, KoehlerE.C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris [see comments]. Eur Heart J21:1000–1008, 2000.
150.
TorzewskiM, RistC, MortensenRF, ZwakaTP, BienekM, WaltenbergerJ, KoenigW, SchmitzG, HombachV, TorzewskiJ.C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol20:2094–2099, 2000.
151.
ZhangYX, CliffWJ, SchoeflGI, HigginsG.Coronary C-reactive protein distribution: Its relation to development of atherosclerosis. Atherosclerosis145:375–379, 1999.
152.
MargaglioneM, CappucciG, ColaizzoD, VecchioneG, GrandoneE, Di MinnoG.C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. Arterioscler Thromb Vasc Biol20:198–203, 2000.
